NEW YORK CITY – Phenomics Health recently became one of only 200 companies worldwide to earn a coveted presentation slot at the 21st annual New York Venture Summit. The New York City-based event connects founders of the hottest venture-backed, emerging, and early-stage companies with an exclusive audience of venture capitalists, corporate investors, private investors, investment…
Plymouth, MI – May 23, 2022 – Phenomics Health Inc., a bioinformatics-based precision medicine company, today announced the commercial integration of six PrecīsMed® pharmacometabolomic (PMx) and PredictScript™ pharmacogenomic (PGx) clinical products to comprehensively support individual patient medication treatment. Phenomics Health novel product platforms can now provide clinicians with multiple tools to enhance treatment outcomes through…
Phenomics Health Inc., a platform bioinformatics-based precision medicine company, today announced completion of clinical product development and validation for its pharmacometabolomics (PMx) PrecīsMed® technology in its new CLIA laboratory located in Michigan Life Science and Innovation Center. The company’s laboratory operations, validation, as well as ongoing research and product development, have been funded with seed financing through experienced healthcare investors.
First Integrated Pharmacogenomics and Metabolomics Platform Offers Potential to Improve Patient Outcomes, Lower Costs in Medication Therapy
Dr. Brian D. Athey, co-founder and Chief Science & Technology Officer of Phenomics Health Inc. (PHI), presented the PHI vision and current activities at the 11th Annual Precision Medicine World Conference (PMWC) in Silicon Valley
End of content
End of content